olaparib,bevacizumab
roche,astrazeneca,merck
['avastin', 'lynparza']
#esmo22: at five-year mark, lynparza kept more patients alive than avastin but missed overall os significance #strategy #competitiveintelligence #marketing #pharma #healthcare #productmarketing #biotech #pharmaceutical 
Strategy & Competitive Marketing | Digital & Social Pharma | Life Sciences Investment | Cell & Gene Therapy | Vaccines